A Gupta1,2, K Al-Dasuqi3, F Xia3,4, G Askin5, Y Zhao5, D Delgado6, Y Wang3,4. 1. From the Department of Radiology (A.G., K.A.-D., F.X., Y.W.) ajg9004@med.cornell.edu. 2. Clinical and Translational Neuroscience Unit (A.G.), Feil Family Brain and Mind Research Institute. 3. From the Department of Radiology (A.G., K.A.-D., F.X., Y.W.). 4. Department of Biomedical Engineering (F.X., Y.W.), Cornell University, Ithaca, New York. 5. Department of Healthcare Policy and Research (G.A., Y.Z.). 6. Samuel J. Wood Library and C.V. Starr Biomedical Information Center (D.D.), Weill Cornell Medicine, New York, New York.
Abstract
BACKGROUND: Concerns have arisen about the long-term health effects of repeat gadolinium injections in patients with multiple sclerosis and the incomplete characterization of MS lesion pathophysiology that results from relying on enhancement characteristics alone. PURPOSE: Our aim was to perform a systematic review and meta-analysis analyzing whether noncontrast MR imaging biomarkers can distinguish enhancing and nonenhancing brain MS lesions. DATA SOURCES: Our sources were Ovid MEDLINE, Ovid Embase, and the Cochrane data base from inception to August 2016. STUDY SELECTION: We included 37 journal articles on 985 patients with MS who had MR imaging in which T1-weighted postcontrast sequences were compared with noncontrast sequences obtained during the same MR imaging examination by using ROI analysis of individual MS lesions. DATA ANALYSIS: We performed random-effects meta-analyses comparing the standard mean difference of each MR imaging metric taken from enhancing-versus-nonenhancing lesions. DATA SYNTHESIS: DTI-based fractional anisotropy values are significantly different between enhancing and nonenhancing lesions (P = .02), with enhancing lesions showing decreased fractional anisotropy compared with nonenhancing lesions. Of the other most frequently studied MR imaging biomarkers (mean diffusivity, magnetization transfer ratio, or ADC), none were significantly different (P values of 0.30, 0.47, and 0.19. respectively) between enhancing and nonenhancing lesions. Of the limited studies providing diagnostic accuracy measures, gradient-echo-based quantitative susceptibility mapping had the best performance in discriminating enhancing and nonenhancing MS lesions. LIMITATIONS: MR imaging techniques and patient characteristics were variable across studies. Most studies did not provide diagnostic accuracy measures. All imaging metrics were not studied in all 37 studies. CONCLUSIONS: Noncontrast MR imaging techniques, such as DTI-based FA, can assess MS lesion acuity without gadolinium.
BACKGROUND: Concerns have arisen about the long-term health effects of repeat gadolinium injections in patients with multiple sclerosis and the incomplete characterization of MS lesion pathophysiology that results from relying on enhancement characteristics alone. PURPOSE: Our aim was to perform a systematic review and meta-analysis analyzing whether noncontrast MR imaging biomarkers can distinguish enhancing and nonenhancing brain MS lesions. DATA SOURCES: Our sources were Ovid MEDLINE, Ovid Embase, and the Cochrane data base from inception to August 2016. STUDY SELECTION: We included 37 journal articles on 985 patients with MS who had MR imaging in which T1-weighted postcontrast sequences were compared with noncontrast sequences obtained during the same MR imaging examination by using ROI analysis of individual MS lesions. DATA ANALYSIS: We performed random-effects meta-analyses comparing the standard mean difference of each MR imaging metric taken from enhancing-versus-nonenhancing lesions. DATA SYNTHESIS: DTI-based fractional anisotropy values are significantly different between enhancing and nonenhancing lesions (P = .02), with enhancing lesions showing decreased fractional anisotropy compared with nonenhancing lesions. Of the other most frequently studied MR imaging biomarkers (mean diffusivity, magnetization transfer ratio, or ADC), none were significantly different (P values of 0.30, 0.47, and 0.19. respectively) between enhancing and nonenhancing lesions. Of the limited studies providing diagnostic accuracy measures, gradient-echo-based quantitative susceptibility mapping had the best performance in discriminating enhancing and nonenhancing MS lesions. LIMITATIONS: MR imaging techniques and patient characteristics were variable across studies. Most studies did not provide diagnostic accuracy measures. All imaging metrics were not studied in all 37 studies. CONCLUSIONS: Noncontrast MR imaging techniques, such as DTI-based FA, can assess MS lesion acuity without gadolinium.
Authors: I Blystad; I Håkansson; A Tisell; J Ernerudh; Ö Smedby; P Lundberg; E-M Larsson Journal: AJNR Am J Neuroradiol Date: 2015-10-15 Impact factor: 3.825
Authors: A Rovira; J Alonso; G Cucurella; C Nos; M Tintoré; S Pedraza; J Rio; X Montalban Journal: AJNR Am J Neuroradiol Date: 1999 Nov-Dec Impact factor: 3.825
Authors: Ludwig Schlemm; Claudia Chien; Judith Bellmann-Strobl; Jan Dörr; Jens Wuerfel; Alexander U Brandt; Friedemann Paul; Michael Scheel Journal: Mult Scler Date: 2016-09-27 Impact factor: 6.312
Authors: Vanessa Wiggermann; Enedino Hernández Torres; Irene M Vavasour; G R Wayne Moore; Cornelia Laule; Alex L MacKay; David K B Li; Anthony Traboulsee; Alexander Rauscher Journal: Neurology Date: 2013-06-12 Impact factor: 9.910
Authors: Ezekiel Maloney; A Luana Stanescu; Francisco A Perez; Ramesh S Iyer; Randolph K Otto; Sarah Leary; Lotte Steuten; Amanda I Phipps; Dennis W W Shaw Journal: Pediatr Radiol Date: 2018-05-22
Authors: Anna Falk Delgado; Danielle Van Westen; Markus Nilsson; Linda Knutsson; Pia C Sundgren; Elna-Marie Larsson; Alberto Falk Delgado Journal: Insights Imaging Date: 2019-08-23
Authors: Christian Thaler; Anna A Kyselyova; Tobias D Faizy; Marie T Nawka; Sune Jespersen; Brian Hansen; Jan-Patrick Stellmann; Christoph Heesen; Klarissa H Stürner; Maria Stark; Jens Fiehler; Maxim Bester; Susanne Gellißen Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240
Authors: Cheryl R McCreary; Marina Salluzzi; Linda B Andersen; David Gobbi; Louis Lauzon; Feryal Saad; Eric E Smith; Richard Frayne Journal: BMJ Open Date: 2020-08-13 Impact factor: 2.692